Ticker Watch

Taylor, Marisa
April 2007
Red Herring;4/30/2007, Vol. 4 Issue 16, p33
Trade Publication
The article presents information on the experimental drug AGI-1067, being tested by Alpharetta, Georgia-based biotechnology company Atherogenics, to treat heart disease. The drug aimed to curb inflammatory response, and pharmaceutical giant AstraZeneca went into partnership to push it along. Scientists and analysts were intrigued, and they waited in anticipation for results from clinical trials. AGI-1067 could be the future of cardiovascular medicine, after all. But then late-phase trials of AGI-1067 failed to reduce incidence of heart attack, cardiovascular death, stroke, unstable angina, and other ailments. And analysts tore into the results, putting Atherogenic's stock in a freefall.


Related Articles

  • AstraZeneca Ditches Deal, AtheroGenics Stock Slips.  // Bioworld Week;4/30/2007, Vol. 15 Issue 18, p3 

    The article reports that the shares of AtheroGenics Inc. dipped 10 percent that its partner AstraZeneca PLC dropped the collaboration of AGI-107, an atherosclerosis drug that missed its Phase III trial in the U.S. Shares of AtheroGenics closed at $3.09 on April 23, and AstraZeneca is looking to...

  • AtheroGenics Seeks New Partner For AGI-1067.  // Bioworld Week;8/27/2007, Vol. 15 Issue 35, p4 

    The article reports that AtheroGenics Inc. was looking for a new partner after it lost its partner, AstraZeneca PLC in the U.S. AstraZeneca PLC terminated the License and Collaboration Agreement with AtheroGenics Inc. regarding the new project AGI-1067. The project will start soon as patient...

  • AstraZeneca Opts Out of Drug Deal, AtheroGenics Stock Slips. Boggs, Jennifer // BioWorld Today;4/24/2007, Vol. 18 Issue 79, p5 

    The article looks at the impact of the decision of AstraZeneca PLC to drop its collaboration with AtheroGenics Inc. on the atherosclerosis drug AGI-1067. The stocks of AtheroGenics dropped by 10% after the decision of AstraZeneca was made. The decision of AstraZeneca is not unexpected since the...

  • Novel drug mechanisms in development for heart failure. Khodjaev, Soidjon; Teerlink, John; Malik, Fady // Pflugers Archiv European Journal of Physiology;Jun2014, Vol. 466 Issue 6, p1219 

    Heart failure therapy has seen many advances over the last 40 years and has rapidly expanded beyond diuretics and digoxin to include several new mechanisms of action and devices whose efficacy had been demonstrated in large clinical trials. The evidence for their use is thoroughly summarized and...

  • Is the life-saving polypill for over-55s a reality? Tanday, Sanjay // GP: General Practitioner;5/16/2008, p16 

    The article reports on the development of the five-in-one polypill, an alternative primary care treatment in Great Britain. According to the media report that a five-in-one polypill could reduce 100,000 premature deaths from heart failures across the country. Five-in-one polypill has undergone...

  • Modern Drug Development. Vaduganathan, Muthiah; Prasad, Vinay // JAMA: Journal of the American Medical Association;12/24/2014, Vol. 312 Issue 24, p2619 

    The authors convey their thoughts on the implications for novel agents being developed in early disease states. Topics discussed include the development of a novel medication for heart failure, maximization of drug benefit and a biological rationale for trial design, and optimization of clinical...

  • CLINIC ROUNDUP.  // BioWorld Today;3/28/2007, Vol. 18 Issue 60, p8 

    This article offers updates on several clinical trials in the U.S. The Phase 1 trial of the combination of systemic ADH-1 plus isolated limb infusion melphalan in melanoma was launched by Adherex Technologies, Inc. The results of the Phase III study of AGI-1067 was released by AtheroGenics, Inc....

  • Cardiovascular News Round-up.  // PharmaWatch: Monthly Review;Jan2005, Vol. 4 Issue 1, p11 

    The article reports global developments related to research studies in the cardiovascular system. Researchers at Wakes Forest University have discovered interleukin-1 receptor associated kinase as a potential atherosclerosis treatment target. Shares of AtheroGenics Inc. drop after its flagship...

  • Liver AE leads to withdrawal of Exanta.  // Reactions Weekly;2/18/2006, Issue 1089, p3 

    Reports on the decision of AstraZeneca to withdraw Exanta from the market and terminate the development of the drug following an adverse event report of serious liver injury in a clinical trial. Observations from the clinical trial of the drug; Advice of AstraZeneca to patients using the drug.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics